Salani Reviews Options for a Patient With Metastatic Endometrial Cancer
September 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Ritu Salani, MD, MBA, discussed trials supporting the use of the immune checkpoint inhibitors pembrolizumab and dostarlimab in patients with metastatic endometrial cancer.
Phillips Discusses Treatment Options for Early-Relapsed DLBCL
September 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Tycel J. Phillips, MD, and participants discussed treatment options for a patient with diffuse large B-cell lymphoma who progressed after 8 months on first-line therapy and prefers to receive outpatient therapy.
Physicians Compare Platinum Rechallenge With Other Second-Line Options in ES-SCLC
September 21st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jason Porter, MD, discussed with participants how they would treat a patient with small cell lung cancer after prior treatment with carboplatin plus etoposide.
Reviewing Options After CAR T-Cell Therapy Progression in R/R DLBCL
September 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mehdi H. Hamadani, MD, discussed the efficacy of therapies for diffuse large B-cell lymphoma after progression on chimeric antigen receptor T-cell therapy. This is the first of 2 articles based on this event.
Traina Reviews Current Data for Antibody-Drug Conjugates in Breast Cancer
September 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Tiffany A. Traina, MD, reviewed data from the TROPiCS-02 and DESTINY-Breast04 and discussed using antibody-drug conjugates in patients with metastatic breast cancer.
Teclistamab Toxicities Highly Manageable in R/R Multiple Myeloma
September 19th 2023In the second article of a 2-part series, Ajay Nooka, MD, MPH, discussed the exciting safety profile of teclistamab and how to manage major adverse events, like cytokine release syndrome, for patients with relapsed/refractory multiple myeloma.
Analyzing Therapeutic Sequencing in Metastatic Prostate Cancer
September 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshi Alumkal, MD, discussed selection of next-line therapy for a patient with metastatic castration-resistant prostate cancer who stopped docetaxel after 4 cycles.
Choosing Appropriate Patients for Dual Immunotherapy/Chemotherapy in NSCLC
September 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed which patients with non–small cell lung cancer should receive immunotherapy-containing regimens. This is the second of 2 articles based on this event.
Survivorship Care “Should Be Considered From the Moment of Diagnosis”
September 17th 2023In an interview with Targeted Oncology™, Alicia K. Morgans, MD, MPH, discussed how the survivorship program at Dana-Farber Cancer Institute helps patients with cancer and ways to incorporate aspects of a survivorship program into more academic and community institutions.
FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC
September 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, discussed subgroup analysis and safety of osimertinib based on the FLAURA trial. This is the second of 2 articles based on this event.
Role of Tolerability in Using Immunotherapy for Metastatic Melanoma
September 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, April K.S. Salama, MD, and other physicians discussed which patients are more challenging when it comes to tolerating dual immunotherapy as frontline therapy for metastatic melanoma. This is the second of 2 articles based on this event.
Safety Results with Cabazitaxel Support Wider Use in mCRPC
September 8th 2023In the second article of a 2-part series, Mehmet A. Bilen, MD, explains how further findings from the phase 3 CARD trial support the wider role cabazitaxel should have in treating patients with metastatic castration-resistant prostate cancer.
Physicians Discuss Immunotherapy Discontinuation in Endometrial Cancer
September 6th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed trials of immune checkpoint inhibition and when to discontinue treatment in patients with endometrial cancer. This is the second of 2 articles based on this event.
Nivolumab plus Cabozantinib Continues to Show Benefit in Advanced RCC
September 5th 2023In the second article of a 2-part series, Rana McKay, MD, discussed follow-up analyses of the phase 3 CheckMate 9ER trial that showed the benefit of nivolumab plus cabozantinib vs sunitinib for patients with advanced renal cell carcinoma.
Roundtable Roundup: Graft-vs-Host Disease
August 31st 2023In separate live virtual events, Pashna N. Munshi, MD; Navneet Majhail, MD, MS; and participants at the respective discussions considered treatment options for a patient with chronic graft-vs-host disease (GVHD) after multiple previous treatment attempts.
Considering Outpatient Use of Tagraxofusp for BPDCN in the Community Setting
August 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with other oncologists concerning the practical considerations for outpatient use of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasm.
The Growing Role of Immunotherapy in Targeting NSCLC
August 30th 2023During a Targeted Oncology™ Community Case Forum™ event in partnership with The Arizona Clinical Oncology Society, Sujith R. Kalmadi, MD, reviewed data from the most important recent phase 3 trials of chemoimmunotherapy in advanced non–small cell lung cancer.
Goals of Managing Cytopenic Myelofibrosis in Younger Patients
August 29th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, and participants discussed the role of JAK inhibitors in managing myelofibrosis particularly in younger patients who may receive allogeneic stem cell transplant. This is the first of 2 articles based on this event.